OR WAIT null SECS
September 27, 2024
The agency is recommending that the market authorization for Oxbryta (voxelotor) be suspended so that emerging data may be reviewed.
September 23, 2024
Approvals were recommended for treatments of ovarian cancer, lung cancer, bleeding disorders, respiratory disease, and more.
September 01, 2024
What impact will the AI Act have on pharma and digital medicine?
August 05, 2024
Germany’s Medical Research Act allows pharmaceutical companies to keep drug prices confidential.
August 04, 2024
Innovative solutions are making personalized cell and gene therapies accessible to all.
July 15, 2024
PRAC is recommending that patients who use glucagon-like peptide-1 receptor agonists (GLP-1 RAs) consider the risk of delayed gastric emptying before undergoing surgery with general anesthesia or deep sedation.
July 01, 2024
EMA’s CHMP gave positive opinions on a nasal delivery for epinephrine and for a first-in-class medicine to treat pulmonary arterial hypertension, among others, including a biosimilar for treatment of autoimmune diseases.
June 25, 2024
In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.
June 19, 2024
PRAC is reviewing the risk of secondary malignancies in patients treated with CAR T-cell medicines.
May 20, 2024
After a review, the agency concluded there was a possible risk of cancer to those exposed to 17-hydroxyprogesterone caproate in the womb.